Friday 6 November 2026
Export TMCI’s income statement to Excel — free account
Treace Medical Concepts, Inc.
TMCI Healthcare Medical Devices
Treace Medical Concepts, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $212.7 million, up 1.59% from fiscal 2024.
- Revenue
- −3.91%
- EPS
- +26.9%
- Free cash flow
- +54.4%
- Total debt
- +5.11%
Quarter to September 2026, against a year earlier
3.95
0.23
−5.50%
Follow TMCI
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 6 Nov | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
2 | 2 | 2 | 2 |
| (58.94%) | (66.88%) | (71.99%) | (73.98%) | ||
| (28.95%) | (31.31%) | (30.72%) | (29.69%) | ||
ROIC |
(35.80%) | (42.93%) | (42.96%) | (39.67%) | |
Return on Tangible Assets |
(44.98%) | (50.43%) | (53.40%) | (52.81%) | |
Average Days of Receivables |
72.34 | 53.45 | 51.08 | 54.24 | |
Free Cash Flow per Share |
(0.47) | (0.40) | (0.38) | (0.28) | |
Free Cash Flow |
(29.49) | (25.96) | (25.05) | (18.57) | |
Capital Expenditures |
(13.52) | (13.04) | (10.47) | (9.83) | |
| Other line items | |||||
Cash ROIC |
(15.42%) | (14.04%) | (14.79%) | (11.78%) | |
Accounts Receivable Turnover |
5.13 | 6.75 | 6.95 | 6.44 | |
Accounts Payable Turnover |
4.98 | 3.14 | 2.34 | 2.74 | |
Inventory Turnover |
1.14 | 1.13 | 1.03 | 0.99 | |
Average Days of Payables |
57.18 | 117.50 | 138.96 | 125.39 | |
Days of Inventory on Hand |
306.29 | 315.65 | 342.12 | 371.35 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
9.54% | 9.33% | 8.87% | 8.87% | |
Selling, General and Administrative Expense of Revenue |
95.74% | 97.27% | 96.74% | 95.07% | |
Share Based Compensation of Revenue |
15.90% | 16.00% | 14.64% | 14.25% | |
Interest Coverage |
(10.18) | (9.99) | (9.23) | (8.17) | |
Operating CF/Net income |
0.27 | 0.21 | 0.24 | 0.16 | |
Depreciation/Fixed assets |
0.36 | 0.30 | 0.28 | 0.00 | |
Capex/Depreciation |
(1.25) | (1.37) | (1.16) | 0.00 | |
Revenue per Share |
3.36 | 3.21 | 3.16 | 3.11 | |
Operating CF per Share |
(0.25) | (0.20) | (0.22) | (0.13) | |
Capex per Share |
(0.21) | (0.20) | (0.16) | (0.15) | |
Capex to Sales |
0.06 | 0.06 | 0.05 | 0.05 |
Columns are period end dates · fundamentals updated 6 Nov 2026